Patients with COPD and type 2 inflammation were found to have less disease after receiving dupilumab.

Published Date: 21 Jun 2023

Patients with type 2 inflammation of chronic obstructive pulmonary disease experienced quick and long-lasting improvements in their condition following treatment with the monoclonal antibody dupilumab, according to a 12-month Phase 3 clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot